December 16, 2016 / 2:28 PM / 7 months ago

BRIEF-Aptevo Therapeutics announces publication of phase 2 clinical data for Otlertuzumab

1 Min Read

Dec 16 (Reuters) - Aptevo Therapeutics Inc :

* "latest data show combination of Otlertuzumab and bendamustine is well tolerated"

* Aptevo - exploring utility of otlertuzumab in combination with additional CLL therapies to evaluate clinical benefit in distinct CLL patient subgroup

* Aptevo Therapeutics announces publication of phase 2 clinical data for otlertuzumab Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below